Humoral response after breakthrough SARS-CoV-2 infection in type 2 diabetes mellitus patients

1 International Diabetes Federation. IDF Diabetes Atlas, 10^th edition. Brussels, Belgium; 2021. [ https://www.diabetesatlas.org] (access: 26.02.2023). Search in Google Scholar

2 Zatońska K, Basiak-Rasała A, Różańska D, Karczewski M, Wołyniec M, Szuba A, et al. Changes in diabetes prevalence and corresponding risk factors – findings from 3- and 6-year follow-up of PURE Poland cohort study. BMC Public Health. 2020;20:843. Search in Google Scholar

3 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44:15-33. Search in Google Scholar

4 Abu-Ashour W, Twells L, Valcour J, Randell A, Donnan J, Howse P, et. al. The association between diabetes mellitus and incident infections: a systematic review and meta-Analysis of observational studies. BMJ Open Diabetes Res Care. 2017;5:e000336. Search in Google Scholar

5 Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012;16:S27-36. Search in Google Scholar

6 Dworzański J, Drop B, Kliszczewska E, Strycharz-Dudziak M, Polz-Dacewicz M. Prevalence of Epstein-Barr virus, human papillomavirus, cytomegalovirus and herpes simplex virus type 1 in patients with diabetes mellitus type 2 in south-eastern Poland. PLoS One, 2019;14:e0222607. Search in Google Scholar

7 Weekly Epidemiological Update on COVID-19 – 1 September 2023. Edition 158. World Health Organization. [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-1-september-2023] (access: 12.09.2023). Search in Google Scholar

8 McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: A cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9:82-93. Search in Google Scholar

9 Norouzi M, Norouzi S, Ruggiero A, Khan MS, Myers S, Kavanagh K, et al. Type-2 diabetes as a risk factor for severe COVID-19 infection. Microorganisms. 2021;9:1211. Search in Google Scholar

10 Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021. Prev Chronic Dis. 2021;18:210123. Search in Google Scholar

11 Vergara-Alert J, Izquierdo-Useros N. An anti-SARS-CoV-2 metabolite is reduced in diabetes. Nat Metab. 2022l;4:501-2. Search in Google Scholar

12 Al-Aly Z. Diabetes after SARS-CoV-2 Infection. Lancet Diabetes Endocrinol. 2023;11:11-3. Search in Google Scholar

13 Chandrashekhar Joshi S, Pozzilli P. COVID-19 Induced Diabetes: A Novel Presentation. Diabetes Res Clin Pract. 2022; 191: 110034. Search in Google Scholar

14 Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges. Diabetes Metab Syndr. 2021;15:505-8. Search in Google Scholar

15 Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of adaptive and innate immunity in type 2 diabetes mellitus. J Diabetes Res. 2018; 2018:7457269. Search in Google Scholar

16 Qiao YC, Shen J, He L, Hong XZ, Tian F, Pan YH, et al. Changes of regulatory T cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Res. 2016;2016:3694957. Search in Google Scholar

17 Han M, Ma K, Wang X, Yan W, Wang H, You J, et al. Immunological characteristics in type 2 diabetes mellitus among COVID-19 patients. Front Endocrinol. 2021;12:596518. Search in Google Scholar

18 Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582. Search in Google Scholar

19 Van Praet JT, Vandecasteele S, De Roo A, Vynck M, De Vriese AS, Reynders M. Dynamics of the cellular and humoral immune response after BNT162b2 messenger ribonucleic acid coronavirus disease 2019 (COVID-19) vaccination in COVID-19-naive nursing home residents. J Infect Dis. 2021;224:1690-3. Search in Google Scholar

20 Sauré D, O’Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22:56-63. Search in Google Scholar

21 Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines (Basel). 2020;8:474. Search in Google Scholar

22 Ali H, Alterki A, Sindhu S, Alahmad B, Hammad M, Al-Sabah S, et al. Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 MRNA COVID-19 vaccination. Front. Immunol. 2021;12:752233. Search in Google Scholar

23 Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, et al. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022;24:849-58. Search in Google Scholar

24 Nomura Y, Sawahata M, Nakamura Y, Kurihara M, Koike R, Katsube O, et al. Age and smoking predict antibody titres at 3 Months after the second dose of the BNT162b2 COVID-19 vaccine. Vaccines. 2021; 9:1042. Search in Google Scholar

25 Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9:999-1009. Search in Google Scholar

26 Virgilio E, Trevisan C, Abbatecola A, Malara A, Palmieri A, Fedele G, et al. Diabetes affects antibody response to SARS-CoV-2 vaccination in older residents of long-term care facilities: Data from the GeroCovid vax study. Diabetes Care. 2022;45:2935-42. Search in Google Scholar

27 Heinz FX, Stiasny K. Distinguishing Features of Current COVID-19 Vaccines: Knowns and unknowns of antigen presentation and modes of action. NJP Vaccines. 2021;6:104. Search in Google Scholar

28 Age-adjusted percentage of obesity for adults with diabetes, United States, 1994-2007. Available from: http://www.cdc.gov/diabetes/statistics/comp/fig7_obesity.htm Accessed 30 March 2023. Search in Google Scholar

29 Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB. Obesity decreases B cell responses in young and elderly individuals. Obesity. 2016;24:615-25. Search in Google Scholar

30 Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahl K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE. 2021;16:e0245424. Search in Google Scholar

31 Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;59:373-90. Search in Google Scholar

32 Soegiarto G, Wulandari L, Purnomosari D, Dhia Fahmita K, Ikhwan Gautama H, Tri Hadmoko S, et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40:4046-56. Search in Google Scholar

33 Zhai X, Qian G, Wang Y, Chen X, Lu J, Zhang Y, et al. Elevated B Cell Activation is associated with type 2 diabetes development in obese subjects. Cell Physiol Biochem. 2016;38:1257-66. Search in Google Scholar

34 Marfella R, Sardu C, D’Onofrio N, Prattichizzo F, Scisciola L, Messina V, et al. Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nat Commun. 2022;13:2318. Search in Google Scholar

35 Cheng Y, Shen P, Tao Y, Zhang W, Xu B, Bi Y, et al. Reduced antibody response to COVID-19 vaccine composed of inactivated SARS-CoV-2 in diabetic individuals. Front Public Health. 2022;10:1025901. Search in Google Scholar

36 Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical Recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546-50. Search in Google Scholar

37 Tan CM, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARSCoV-2 surrogate virus neutralization test (sVNT) based on antibody mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073-8. Search in Google Scholar

38 Boroumand AB, Forouhi M, Karimi F, Moghadam AS, Naeini LG, Kokabian P, et al. Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review. Front Immunol. 2022; 13:940357. Search in Google Scholar